Active substance | nivolumab + ipilimumab |
Holder | BMS |
Status | Running |
Indication | Treatment of adult patients with unresectable malignant pleural mesothelioma that have progressed after at least one line of treatment, including platinumbased doublet chemotherapy. |
Public documents | Approbation |
Information for the patient | |
Informed consent | |
Last update | 09/03/2022 |